Kornimate/medical-research-clean huggingface dataset:
home pulmonary rehabilitation for copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD); Emphysema

Summary: regular physical activity has been found to be important in maintaining health and well-being in people with copd. the purpose of this study is to test new technology and health coaching aimed to help people with copd become more physically active in their daily lives.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd, confirmed by spirometry * age ≥40 years (to avoid recruiting participants with asthma rather than copd) * current or previous smoker (≥10 packs per year) * confidence in using the proposed pulmonary rehabilitation (pr) system * english language fluency exclusion criteria: * study candidate experiencing an acute copd exacerbation (can be included after the acute event) * inability to walk (orthopedic-neurologic problems or confined to a bed) * currently in pr or finished pr in the last three months (unlikely to improve) * pregnant women * live in an area where cell phones do not work/

Keywords: pulmonary rehabilitation
bread structure and postprandial metabolic responses

Conditions: Postprandial Hyperglycemia

Summary: the structural properties of bread are considered one of the most important factors that can affect its digestibility, glucose homeostasis and postprandial metabolic responses. the purpose of this study is to examine the effects of consumption of less processed whole grain bread products (wheat and fortified with legumes) in comparison with finely milled whole grain bread products on postprandial glycaemic response and appetite regulation.

postprandial glucose response caused by bread products of different degree of processing, as well as their appetite regulating properties will be evaluated. in the intervention there are totally four samples, the reference (white wheat bread), the less processed whole wheat bread, the whole wheat bread fortified with finely milled legumes (chickpeas), the whole wheat bread fortified with less processed legumes (chickpeas). the volunteers that will be enrolled in the study should be apparently healthy subjects (women and men) with normal body weight. certain effects related to the structure of the different products on glycemic and insulinemic responses, subjective appetite ratings and other parameters will be examined.

Eligibility criteria:
inclusion criteria: * normal exercise and dietary habbits * weight stable for at least 3 months before enrollment exclusion criteria: * pregnancy and lactation * diabetes * chronic medical illness * regular intense exercise (\>5 hrs/week) * alcohol consumption \>2 drinks/day

Keywords: bread food structure glycemic control appetite regulation
gemox-haic plus gem-sys in combination with lenvatinib and pd-1 inhibitor for large unresectable icc

Conditions: Intrahepatic Cholangiocarcinoma

Summary: this study aimed to preliminarily evaluate the clinical efficacy and safety of hepatic arterial infusion chemotherapy (haic) of gemcitabine and oxaliplatin (gemox) plus systemic gemcitabine chemotherapy (gem-sys) combined with lenvatinib and programmed cell death protein-1 (pd-1) inhibitor in patients with large unresectable intrahepatic cholangiocarcinoma (uicc). large uicc patients who underwent gemox-haic (day 1) and gem-sys (day 8) (3w/cycle) combined with lenvatinib and pd-1 inhibitor between november 2019 and december 2022 were enrolled. clinical data were retrospectively collected to analyze local tumor response, progression-free survival (pfs), overall survival (os), and adverse events (aes). tumor response was assessed by the response evaluation criteria in solid tumors (recist) version 1.1. aes were evaluated by the common terminology criteria for adverse events (ctcae) version 5.0. in this study, os was the primary endpoint, and progression-free survival (pfs) was the secondary endpoint.


Eligibility criteria:
inclusion criteria: (a) age of 18-70 years; (b) eastern cooperative oncology group (ecog) performance status score of 0 or 1; (c) diagnosis of icc by histopathological examination of tissue biopsy specimens; (d) unresectable icc confirmed by a multidisciplinary staff including at least one experienced liver surgeon; (e) tumor size larger than 5 cm in maximum diameter; (f) adequate liver function (total bilirubin \ 3,000/mm3, hemoglobin\>9.0g/dl and platelet count \>100,000/mm3 ) and adequate coagulation function (prothrombin activity \> 40% and international normalized ratio (inr) \< 1.26); (g) patients received at least two cycles of gemox-haic + gem-sys combined with lenvatinib and pd-1 inhibitor; (h) patients with regular clinical data for evaluating the clinical efficacy and safety. exclusion criteria: (a) combined with other malignancies; (b) patients underwent any other chemotherapy regimens before, including gemcitabine and oxaliplatin; (c) patients received previous surgical resection or any other interventional procedures besides haic, such as transarterial chemoembolization (tace), 125i seed implantation, radiofrequency ablation, microwave ablation, cryoablation, or percutaneous ethanol injection, etc.; (d) drug (chemotherapy drugs, lenvatinib, or pd-1 inhibitors) allergy; (e) patients with a history of autoimmune diseases; (f) patients with gastrointestinal bleeding of any grade within 4 weeks prior to the integrated treatment; (g) patients with uncontrolled comorbidities (e.g. general infection, serious dysfunction of heart or kidney, acute hepatitis or pneumonia, chronic obstructive pulmonary disease, or recent stroke).

Keywords: intrahepatic cholangiocarcinoma hepatic arterial infusion chemotherapy immune checkpoint inhibitor tyrosine kinase inhibitor
effect of konjac-mannan in individuals with insulin-resistance syndrome

Conditions: Insulin Resistance Syndrome

Summary: to study whether a diet high in fiber from konjac-mannan (kjm) has an effect on metabolic control in individuals with insulin resistance syndrome.


Eligibility criteria:
inclusion criteria: * impaired glucose tolerant * clinical absent of chd * bmi less than 30 kg/m2 * presence of full insulin resistance syndrome * reduced hdl cholesterol * elevated serum triglycerides * moderate hypertension exclusion criteria: * regular smoking * regular alcohol consumption * family history of premature coronary heart disease * hypothyroidism * renal, hepatic or gastrointestinal disease * taking medications for hyperglycemia * taking medications for hyperlipidemia * taking medications for hypertension

Keywords: insulin resistance syndrome fiber konjac
brain outcomes with lifestyle change in down syndrome

Conditions: Down Syndrome; Alzheimer Disease; Obesity

Summary: the goal of this study is to determine if weight loss or changes in dietary intake can help prevent of delay adults with down syndrome from developing alzheimer's disease adults with down syndrome without dementia will be randomized to either a weight loss group or a general health education control group. the weight loss group will be asked to follow a reduced energy diet, attend monthly education sessions delivered remotely and self-monitor diet and body weight using commercially available web-based applications. the control group will be asked to attend remotely delivered monthly education sessions on general health education topics. all participants will come to the university of kansas medical center, 3 times across 12 months for a blood draw, cognitive testing, a mri, assessment of height and weight, and assessment of diet intake.


Eligibility criteria:
inclusion criteria: * diagnosis of down syndrome * bmi of 25 to 50 kg/m2 * ability to communicate through spoken language. * ability to come to the university of kansas medical center 3 times across 1 year for outcomes testing * living at home with a parent/guardian, or in a supported living environment with a caregiver who assists with food shopping, meal planning, and meal preparation and agrees to serve as a study partner including providing transportation to our facilities for study assessments. exclusion criteria: * diagnosis of dementia * insulin dependent diabetes * participation in a weight management program involving diet or physical activity in the past 6 mos. * dairy allergy * serious medical risk (e.g., cancer, recent heart attack, stroke, pregnancy, angioplasty) * unwilling to be randomized * contraindications for mri, including metal implants or devices incompatible with mri such as pacemakers, claustrophobia, and inability to lay in a supine position * use of glp-1 medications * use of anti-amyloid medications
newborn screening for spinal muscular atrophy

Conditions: Spinal Muscular Atrophy

Summary: to test if the routine newborn screening dried blood spots can be used to test if missing 2 copies of smn1 gene, a status indicating spinal muscular atrophy

parents of newborns will be invited to test if their newborns are affected with sma. the routine newborn screening dried blood spots sample will be used to test if missing 2 copies of smn1 gene. if positive of screening test, further confirmation tests including physical examination and other methology for smn1 gene copies quantification will be provided. genetic counseling and treatment option will be provided, too.

Eligibility criteria:
inclusion criteria: * babies born in taiwan receive regular new born screening suggested by ministry of heath and welfare. * parents or legal guardian sign in the informed consent form. exclusion criteria: * parents or legal guardian do not agree to sign in the informed consent form.

Keywords: newborn screening , spinal muscular atrophy
evaluation of carboplatin/paclitaxel/bevacizumab in the treatment of advanced stage endometrial carcinoma

Conditions: Endometrial Cancer

Summary: purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(avastin) in patients with advanced stage endometrial carcinoma.

the purpose of this study is to test the effectiveness, safety, and tolerability of the drug combination carboplatin, paclitaxel, and bevacizumab(avastin) in patients with advanced stage endometrial carcinoma. this is a phase ii,open label,single center study. patients will receive carboplatin, paclitaxel, and bevacizumab in an outpatient center by intravenous administration. the primary objectives is to study the progression free survival at 24 months after initiation of treatment and to determine the toxicity profile of the drug combinations. the secondary objectives are to estimate the overall survival and tumor response for this group of patients.

Eligibility criteria:
inclusion criteria: * advanced stage endometrial cancer (stage 3 or 4) * any histology including clear cell, and serous papillary carcinomas * surgery must have had hysterectomy and bilateral salpingo-oophorectomy * chemotherapy initiated 12 weeks after surgery * sign informed consent * adequate end-organ function * gog (gynecologic oncology group)performance status 0,1,2 * patients must be 18 years or older * patients may have received radiation for the treatment of endometrial cancer. * patients may have measurable or non-measurable disease. exclusion criteria: * patient with concomitant malignancy other than non-melanoma skin cancer * patients with prior malignancy who have been disease free for 5 years. * patients with serious uncontrolled infection, angina or serious peripheral neuropathy. * patients whose circumstances will not permit study completion or adequate follow up * patients who have received prior cytotoxic chemotherapy for treatment of endometrial cancer including chemotherapy used for radiation sensitization.

Keywords: endometrial cancer advanced stage endometrial cancer stage 3 or 4 endometrial cancer cancer treatment gyn cancer
postoperative patient controlled epidural analgesia after total knee arthroplasty with 2ug/ml fentanyl combine with 0.2% ropivacaine or 0.2% levobupivcaine

Conditions: Arthroplasty, Replacement, Knee; Patient-controlled Analgesia

Summary: postoperative epidural analgesia (ea) is an effective and well-accepted modality of pain relief technique after having total knee replacement operation(1,4). patient controlled epidural analgesia (pcea) has been shown to be safe and effective in standard ward setting(2) and results in reduced epidural analgesic requirements(3). besides, it also bear the advantage of avoidance of overdose, reduction of waiting times and involvement of patients in their analgesic regimen(3). both ropivacaine and levobupivacaine are the local anaesthetic using in epidural analgesia which has been proven to be safe and effective(4). 0.2% ropivacaine with 2ug/ml fentanyl has been used in our locality for more than 8 years. another local anaesthetics, levobupivacaine, a s-enantiomer of bupivacaine has come up in hong kong, which has been proved to be safe, effective and may be better value for money. these two drugs has been proven to have similar analgesic potency in using as ea for postoperative pain relief for other operation(5,6,7) and for orthropaedics operation but in different concentration(4). concerns have been raised about the introduction of the levobupivacaine in the departmental protocol. objectives of this study are a)to determine the equivalence of two local anaesthetics regimen ; 0.2% ropivacaine with 2ug/ml fentanyl and 0.2% levobupivacaine with 2ug/ml fentanyl and b) to assess the cost-effectiveness of using these two regimens. the null hypothesis is that the difference of analgesic effect, presented with visual analogue score, of two patient controlled epidural analgesia regimen, the 0.2% ropivacaine with 2 ug/ml fentanyl and 0.2% levobupivacaine with 2ug/ml fentanyl is higher than the threshold of 9 mm vas. (8,9,10)


Eligibility criteria:
inclusion criteria: * \> 18 years old, asa i -iii and * undergoing total knee arthroplasty * combine spinal-epidural anaesthesia exclusion criteria: * known hypersensitivity to amide-type local anaesthetics * known hypersensitivity to opioids * known history of severe cardiovascular, renal, hepatic, neurological or psychiatric disease as judged by the investigator * known history of peripheral neuropathies * those receiving chronic analgesic therapy, or any contraindication for epidural analgesia (e.g. clotting disorders, or history of lumbar surgery) * inability to perform a pain score, or pregnancy or lactation

Keywords: post total knee replacement patient control epidural analgesia
non-interventional study of tocilizumab subcutaneous (sc) monotherapy in participants with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the aim of this non-interventional study in hungarian participants is to gather real life data about the efficacy and safety of tocilizumab sc monotherapy in ra, to assess data about pattern of usage of tocilizumab monotherapy in ra disease management.


Eligibility criteria:
inclusion criteria: * moderate to severe ra according to 2010 american college of rheumatology (acr) and european league against rheumatism (eular) joint criteria * treatment with tocilizumab sc monotherapy for up to 8 weeks prior to enrollment, under the prescriptive authority of a physician who has made the decision to commence tocilizumab in accordance with the local label * methotrexate intolerance, or inadequate response to prior dmards and tnf inhibitors where continued methotrexate treatment was deemed inappropriate exclusion criteria: * treatment with tocilizumab more than 8 weeks prior to enrollment * failure to meet local tocilizumab label indication criteria * treatment with any investigational agent within 4 weeks of beginning tocilizumab sc monotherapy * last methotrexate dose within 1 week of beginning tocilizumab sc monotherapy * history of any other autoimmune or joint inflammatory disease
pet your stress away study

Conditions: Stress, Physiological; Stress, Psychological

Summary: the purpose of this study is to determine whether an animal visitation programs on college campuses are effective in the treatment of college student stress reduction during preparation for final examinations.


Eligibility criteria:
inclusion criteria: * undergraduate status exclusion criteria: * none
fluticasone furoate/gw642444 inhalation powder long-term safety study

Conditions: Asthma

Summary: the purpose of this study is to evaluate the long-term safety of fluticasone furoate/gw642444


Eligibility criteria:
inclusion criteria: * clinical diagnosis of asthma * reversibility fev1 of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol * fev1 greater than or equal to fifty percent of predicted * currently using moderate to high dose inhaled corticosteroid therapy exclusion criteria: * history of life threatening asthma * respiratory infection or oral candidiasis * asthma exacerbation * uncontrolled disease or clinical abnormality * allergies * taking another investigational medication or prohibited medication
single-center retrospective study : developmental trajectories of children born prematurely before 32 weeks assessed with the revised brunet lézine scale at 1, 2 and 3 years

Conditions: Premature Birth

Summary: this study will assess professionals in the chi créteil neonatal department and the val de marne perinatal network to gain a better understanding of the developmental trajectories of children hospitalized at the chi créteil, with a view to optimizing their care in the long term


Eligibility criteria:
inclusion criteria: * children born at chi créteil between 2012 and 2022, included in the val de marne perinatal network. * children seen in pediatrician-psychomotor consultation with assessment by the blr scale at 1 year ac. exclusion criteria: * children born with a term of birth ≥ 32 weeks + 1 day. * child removed from the val de marne perinatal network monitoring from the age of 1 year ac: death or parental decision. * children presenting with cerebral palsy, blindness or deafness at the age of 1 year ac.

Keywords: developmental trajectories revised brunet lézine movement and posture language socialization coordination
striving towards empowerment and medication adherence r01

Conditions: Hiv; Mental Health Issue

Summary: this is a study for black women living with hiv to test a counseling program for black women living with hiv. this participant may be a good fit if the participant is a black woman, living with hiv, has a history of trauma, and is currently taking antiretroviral therapy (art) medicines


Eligibility criteria:
inclusion criteria: 1. black 2. living with hiv 3. cis-gender female 4. age 18 or older 5. english speaking 6. viral load non-suppression (\>200 ml) within the past year or a lack of hiv viral load measure for 6 consecutive months or more during the past 12 months 7. history of trauma/abuse 8. capable of completing and fully understanding the informed consent process and study procedures exclusion criteria: 1. unable to completely and fully understand the informed consent process and the study procedures 2. significantly interfering mental health symptoms (e.g., active psychosis that is untreated)

Keywords: hiv black women trauma intersectional discrimination stigma medication adherence
low sirtuin-1 levels are linked to erythropoietin resistance in hemodialysis patients.

Conditions: Chronic Kidney Disease; Hemodialysis; Anemia in End Stage Renal Disease; Erythropoietin

Summary: this study investigates the relationship between sirtuin-1 (sirt1) levels and erythropoietin resistance in hemodialysis patients. the study aims to determine whether low sirt1 levels contribute to epo resistance and to explore the potential mechanisms involved. blood samples and clinical data from hemodialysis patients will be analyzed to evaluate this relationship.

this study explores the association between sirtuin-1 (sirt1) levels and erythropoietin resistance in hemodialysis patients. erythropoiesis-stimulating agents (esas) are commonly used to treat anemia in chronic kidney disease (ckd) patients undergoing hemodialysis. however, a significant proportion of patients exhibit hyporesponsiveness to esas, leading to suboptimal anemia management. sirt1, a nicotinamide adenine dinucleotide (nad+)-dependent histone deacetylase, regulates hypoxia and iron metabolism by modulating the activity of hypoxia-inducible factor 1α (hif-1α). lower sirt1 levels may impair hif-1α activity and contribute to reduced erythropoietin (epo) responsiveness. in this multicentric cross-sectional cohort study, 391 adult hemodialysis patients from provincial dialysis clinics in bursa, turkey, were enrolled between august 2020 and march 2021. esa responsiveness was assessed using the erythropoietin resistance index (eri), calculated as the weekly weight-adjusted esa dose divided by hemoglobin concentration. serum sirt1 levels were measured using a human sirt1 elisa kit. the study aims to determine whether low sirt1 levels are independently associated with higher eri scores and to identify other clinical and biochemical parameters influencing esa responsiveness. multiple regression and correlation analyses will be performed to evaluate the relationship between sirt1 levels, eri scores, ferritin levels, and other clinical factors. logistic regression will also be conducted to explore whether sirt1 is an independent predictor of high eri scores (≥50th percentile). the findings from this study may provide new insights into the molecular mechanisms underlying esa resistance and highlight the potential role of sirt1 as a target for improving anemia management in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * aged ≥18 years * receiving hemodialysis * availability of laboratory data to calculate eri exclusion criteria: * autosomal polycystic kidney disease * malignancies * infectious diseases * chronic rheumatological disorders * vitamin b12 or folic acid deficiency * crp levels ≥ 5 mg/l * pth levels ≥ 300 pg/dl * inadequate hemodialysis (kt/vurea \< 1.2)
atypical lesions of the breast: close observation versus excision (alcove)

Conditions: Atypical Ductal Hyperplasia (ADH) of the Breast

Summary: this study is designed to look at whether it is feasible to observe women with atypical ductal hyperplasia (adh) of the breast, or whether surgical excision is necessary.

we hypothesize that surgical excision may not yield an improvement in survival over hormonal therapy and/or close observation alone in patients who present with adh on core needle biopsy of the breast. an alternate (non-inferior) strategy for management may be possible, and may be associated with improved quality of life and fewer complications, and lower overall costs. although several researchers have suggested a clinical trial to investigate this idea this would be the first time it has been done, and could therefore be practice changing.

Eligibility criteria:
inclusion criteria a patient/subject is eligible for enrollment if all of the following inclusion criteria are met: 1. pre- and post-menopausal women ≥ 40 years of age with newly diagnosed adh, histologically confirmed on breast core biopsy. 2. ability to understand and the willingness to sign a written informed consent document. 3. willing to schedule definitive resection of adh if randomized to surgical excision arm or be observed if randomized to the observation arm. 4. original breast core biopsy specimen available for pathologic review and staining by yale school of medicine department of pathology. exclusion criteria a patient/subject will not be eligible for this study if any of the following exclusion criteria are met: 1. patients with a current breast cancer diagnosis or a personal history of cancer 2. patients with a personal history of an identifiable genetic mutation (brca) for breast cancer and, untested first degree relatives of mutation carriers 3. patients who have previously or are currently taking tamoxifen or exemestane or other chemotherapy or biologic therapy (e.g. trastuzumab) 4. patients with a history of radiation therapy to the chest wall 5. pregnant and/or lactating women within past 6 months.